A Cisplatin‐Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy

Abstract

Dieser Beitrag wurde nach Begutachtung und Überarbeitung sofort als "akzeptierter Artikel" (Accepted Article; AA) publiziert und kann unter Angabe der unten stehenden Digitalobjekt-Identifizierungsnummer (DOI) zitiert werden. Die deutsche Übersetzung wird gemeinsam mit der endgültigen englischen Fassung erscheinen. Die endgültige englische Fassung (Version of Record) wird ehestmöglich nach dem Redigieren und einem Korrekturgang als Early-View-Beitrag erscheinen und kann sich naturgemäß von der AA-Fassung unterscheiden. Leser sollten daher die endgültige Fassung, sobald sie veröffentlicht ist, verwenden. Für die AA-Fassung trägt der Autor die alleinige Verantwortung.Zitierweise: Angew. Chem. Int. Ed.Abstract: The efficacy of conventional chemotherapy is hindered by cancer cells' escape from the immune system. Herein, we report a multifunctional nanohybrid system for effective immunochemotherapy against cervical cancer. This nanohybrid contains both immune checkpoint inhibitor and cisplatin anticancer prodrug, showing improved cellular accumulation and increased binding of Pt to DNA and resulting in elevated apoptosis than using cisplatin alone when tested in cervical cancer cells. Intriguingly, the use of immune checkpoint inhibitors enables the inhibition of indoleamine-2,3dioxygenase and reverses immunosuppressive T cells to recognize cancer cells, leading to T cell proliferation and activation, cancer cell cycle arrest, and ultimately increased cancer cell death. The nanohybrid is also active in vivo against the growth of human cervical tumor. Overall, we provide a novel strategy using a multifunctional nanohybrid system to boost the antitumor activity of cisplatin, the gold standard chemotherapeutic treatment for cervical cancer.

Biocompatible Hydrotalcite Nanohybrids for Medical Functions

“…In biomedical applications, one of the most significant factors in utilizing layered nanomaterials is biocompatibility. Among various 2D layered crystal structures, LDHs have been established as highly biocompatible, and their related nanohybrids are readily applicable for therapeutic and diagnostic uses such as anti-cancer, anti-inflammatory, antibiotic, antioxidant efficacy, and bio-imaging [33][34][35][36][37][38][39][40][41][42][43][44]. As has been well documented, efficient drug delivery carriers should not only be biocompatible to ensure safety aspects of nano delivery vehicles, but also be suitable to stabilize and protect biomolecules against harsh physical and biochemical attacks in biological environments, subsequently to deliver genes/drugs into the target-specific tissue and release them in the controlled manner.…”

Recent progress in layered double hydroxides as a cancer theranostic nanoplatform

“…Recently, the research trend in DDSs with LDHs is changing to be in direction of giving multiplex therapies for radiation‐, immune‐, and photo‐thermal ones (G. Choi, Jeon, et al, 2018; N. Wang et al, 2018; L. Yang et al, 2019; Zhang et al, 2019). As demonstrated by radiation therapy, Choy et al studied LDH nanocarrier for boron delivery to the boron neutron capture therapy (BNCT).…”

Functional Layered Double Hydroxide Nanohybrids for Biomedical Imaging

“…There are some studies on LDH-based nanohybrids for multimodal imaging as well as desirable combination therapies, which use more than one medication or modality to realize synergistic treatment. LDHs have been extensively studied as a theranostic delivery carrier for a variety of therapies, including chemo-, gene-, photo-, boron neutron capture-, and even immunotherapy [64,65,66,67,68,69,70,71,72,73,74,75,76,77,78].…”